Sanofi plans up to USD 1.6 billion investment in Germany: Handelsblatt
Frankfurt: French pharmaceutical company, Sanofi, is close to deciding on an investment ranging between 1.3 billion euros and 1.5 billion euros ($1.4-$1.6 billion) for its primary production facility in Frankfurt, Germany. This site manufactures the insulin brand Lantus, newspaper Handelsblatt reported on Monday.
Sanofi did not immediately respond to a request for comment, as per Reuters.
Among recent wins by Germany's ruling coalition to attract healthcare investments, Daiichi Sankyo said in February it would spend about 1 billion euros to boost its work on precision cancer drugs near Munich.
U.S. drugmaker Eli Lilly in November last year pledged to invest 2.3 billion euros to make obesity and diabetes drugs in Germany
Read also: Sanofi names Audrey Duval Derveloy as Executive Vice President, Global Head of Corporate Affairs
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd